These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 18627399)

  • 1. Contrasting human cytokine responses to promastigote whole-cell extract and the Leishmania analogue receptor for activated C kinase antigen of L. amazonensis in natural infection versus immunization.
    Azeredo-Coutinho RB; Matos DC; Armôa GG; Maia RM; Schubach A; Mayrink W; Mendonça SC
    Clin Exp Immunol; 2008 Sep; 153(3):369-75. PubMed ID: 18627399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro responses of human peripheral blood mononuclear cells to whole-cell, particulate and soluble extracts of Leishmania promastigotes.
    Telino E; De Luca PM; Matos DC; Azeredo-Coutinho RB; Meirelles MN; Conceição-Silva F; Schubach A; Mendonça SC
    Clin Exp Immunol; 2006 Feb; 143(2):338-44. PubMed ID: 16412059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T-cell responsiveness of American cutaneous leishmaniasis patients to purified Leishmania pifanoi amastigote antigens and Leishmania braziliensis promastigote antigens: immunologic patterns associated with cure.
    Coutinho SG; Oliveira MP; Da-Cruz AM; De Luca PM; Mendonça SC; Bertho AL; Soong L; McMahon-Pratt D
    Exp Parasitol; 1996 Nov; 84(2):144-55. PubMed ID: 8932764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of immune responses and protection induced by A2 and nucleoside hydrolase (NH) DNA vaccines against Leishmania chagasi and Leishmania amazonensis experimental infections.
    Zanin FH; Coelho EA; Tavares CA; Marques-da-Silva EA; Silva Costa MM; Rezende SA; Gazzinelli RT; Fernandes AP
    Microbes Infect; 2007 Jul; 9(9):1070-7. PubMed ID: 17644455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Flow cytometric determination of cellular sources and frequencies of key cytokine-producing lymphocytes directed against recombinant LACK and soluble Leishmania antigen in human cutaneous leishmaniasis.
    Bottrel RL; Dutra WO; Martins FA; Gontijo B; Carvalho E; Barral-Netto M; Barral A; Almeida RP; Mayrink W; Locksley R; Gollob KJ
    Infect Immun; 2001 May; 69(5):3232-9. PubMed ID: 11292745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro evaluation of a soluble Leishmania promastigote surface antigen as a potential vaccine candidate against human leishmaniasis.
    Chamakh-Ayari R; Bras-Gonçalves R; Bahi-Jaber N; Petitdidier E; Markikou-Ouni W; Aoun K; Moreno J; Carrillo E; Salotra P; Kaushal H; Negi NS; Arevalo J; Falconi-Agapito F; Privat A; Cruz M; Pagniez J; Papierok GM; Rhouma FB; Torres P; Lemesre JL; Chenik M; Meddeb-Garnaoui A
    PLoS One; 2014; 9(5):e92708. PubMed ID: 24786587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design of multi-epitope peptides containing HLA class-I and class-II-restricted epitopes derived from immunogenic Leishmania proteins, and evaluation of CD4+ and CD8+ T cell responses induced in cured cutaneous leishmaniasis subjects.
    Hamrouni S; Bras-Gonçalves R; Kidar A; Aoun K; Chamakh-Ayari R; Petitdidier E; Messaoudi Y; Pagniez J; Lemesre JL; Meddeb-Garnaoui A
    PLoS Negl Trop Dis; 2020 Mar; 14(3):e0008093. PubMed ID: 32176691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection.
    Coelho EA; Tavares CA; Carvalho FA; Chaves KF; Teixeira KN; Rodrigues RC; Charest H; Matlashewski G; Gazzinelli RT; Fernandes AP
    Infect Immun; 2003 Jul; 71(7):3988-94. PubMed ID: 12819086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Total Leishmania antigens with Poly(I:C) induce Th1 protective response.
    Sanchez MV; Eliçabe RJ; Di Genaro MS; Germanó MJ; Gea S; García Bustos MF; Salomón MC; Scodeller EA; Cargnelutti DE
    Parasite Immunol; 2017 Nov; 39(11):. PubMed ID: 28901553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antigenicity of
    Fernández L; Carrillo E; Sánchez-Sampedro L; Sánchez C; Ibarra-Meneses AV; Jimenez MA; Almeida VDA; Esteban M; Moreno J
    Front Immunol; 2018; 9():843. PubMed ID: 29740446
    [No Abstract]   [Full Text] [Related]  

  • 11. Evaluation of amastigote reactive cells in human cutaneous leishmaniasis caused by Leishmania aethiopica.
    Maasho K; McMahon-Pratt D; Raita J; Raud M; Britton S; Soong L; Akuffo H
    Clin Exp Immunol; 2003 May; 132(2):316-22. PubMed ID: 12699423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction and abrogation of LACK reactive cells in the evolution of human leishmaniasis.
    Maasho K; Wolday D; Edjigu M; Söderström K; Britton S; Akuffo H
    Clin Exp Immunol; 2001 May; 124(2):255-61. PubMed ID: 11422202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of vaccinal effectiveness of preparations containing membrane antigens of Leishmania (L.) amazonensis in experimental cutaneous leishmaniasis model.
    Ribeiro JG; Ferreira AS; Macedo SRA; Rossi NRDLP; da Silva MCP; Guerra RNM; de Barros NB; Nicolete R
    Int Immunopharmacol; 2017 Jun; 47():227-230. PubMed ID: 28433944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effects of antigens from L. braziliensis isolates from disseminated and cutaneous leishmaniasis on in vitro cytokine production.
    Leopoldo PT; Machado PR; Almeida RP; Schriefer A; Giudice A; de Jesus AR; Ho JL; Guimarães LH; Bacellar O; Carvalho EM
    BMC Infect Dis; 2006 Apr; 6():75. PubMed ID: 16638143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of vaccination with a combination of Leishmania amastigote antigens and the lipid A-analogue ONO-4007 for immunoprophylaxis and immunotherapy against Leishmania amazonensis infection in a murine model of New World cutaneous leishmaniasis.
    Calvopina M; Barroso PA; Marco JD; Korenaga M; Cooper PJ; Nonaka S; Hashiguchi Y
    Vaccine; 2006 Jul; 24(27-28):5645-52. PubMed ID: 16621179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunologic response and memory T cells in subjects cured of tegumentary leishmaniasis.
    Carvalho AM; Magalhães A; Carvalho LP; Bacellar O; Scott P; Carvalho EM
    BMC Infect Dis; 2013 Nov; 13():529. PubMed ID: 24206576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12.
    Skeiky YA; Guderian JA; Benson DR; Bacelar O; Carvalho EM; Kubin M; Badaro R; Trinchieri G; Reed SG
    J Exp Med; 1995 Apr; 181(4):1527-37. PubMed ID: 7699334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokine and nitric oxide patterns in dogs immunized with LBSap vaccine, before and after experimental challenge with Leishmania chagasi plus saliva of Lutzomyia longipalpis.
    Resende LA; Roatt BM; Aguiar-Soares RD; Viana KF; Mendonça LZ; Lanna MF; Silveira-Lemos D; Corrêa-Oliveira R; Martins-Filho OA; Fujiwara RT; Carneiro CM; Reis AB; Giunchetti RC
    Vet Parasitol; 2013 Dec; 198(3-4):371-81. PubMed ID: 24129068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antigenic extracts of Leishmania braziliensis and Leishmania amazonensis associated with saponin partially protects BALB/c mice against Leishmania chagasi infection by suppressing IL-10 and IL-4 production.
    Grenfell RF; Marques-da-Silva EA; Souza-Testasicca MC; Coelho EA; Fernandes AP; Afonso LC; Rezende SA
    Mem Inst Oswaldo Cruz; 2010 Sep; 105(6):818-22. PubMed ID: 20944999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can interferon-gamma and interleukin-10 balance be associated with severity of human Leishmania (Viannia) braziliensis infection?
    Gomes-Silva A; de Cássia Bittar R; Dos Santos Nogueira R; Amato VS; da Silva Mattos M; Oliveira-Neto MP; Coutinho SG; Da-Cruz AM
    Clin Exp Immunol; 2007 Sep; 149(3):440-4. PubMed ID: 17614975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.